MX2017011251A - DIMEROS SCFV-FC QUE SE UNEN AL FACTOR DE CRECIMEINTO TRANSFORMANTE ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD. - Google Patents
DIMEROS SCFV-FC QUE SE UNEN AL FACTOR DE CRECIMEINTO TRANSFORMANTE ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD.Info
- Publication number
- MX2017011251A MX2017011251A MX2017011251A MX2017011251A MX2017011251A MX 2017011251 A MX2017011251 A MX 2017011251A MX 2017011251 A MX2017011251 A MX 2017011251A MX 2017011251 A MX2017011251 A MX 2017011251A MX 2017011251 A MX2017011251 A MX 2017011251A
- Authority
- MX
- Mexico
- Prior art keywords
- scfv
- high affinity
- dimeros
- specificity
- join
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128133P | 2015-03-04 | 2015-03-04 | |
| PCT/US2016/020779 WO2016141244A1 (en) | 2015-03-04 | 2016-03-03 | scFv-Fc DIMERS THAT BIND TRASFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011251A true MX2017011251A (es) | 2018-02-19 |
Family
ID=55538640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011251A MX2017011251A (es) | 2015-03-04 | 2016-03-03 | DIMEROS SCFV-FC QUE SE UNEN AL FACTOR DE CRECIMEINTO TRANSFORMANTE ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD. |
| MX2022007456A MX2022007456A (es) | 2015-03-04 | 2017-08-31 | Dimeros scfv-fc que se unen al factor de crecimiento transformante-?1 con alta afinidad, avidez y especificidad. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007456A MX2022007456A (es) | 2015-03-04 | 2017-08-31 | Dimeros scfv-fc que se unen al factor de crecimiento transformante-?1 con alta afinidad, avidez y especificidad. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10508146B2 (enExample) |
| EP (2) | EP3265484B1 (enExample) |
| JP (1) | JP6845802B2 (enExample) |
| KR (3) | KR102754133B1 (enExample) |
| CN (1) | CN107889491B (enExample) |
| AR (1) | AR103839A1 (enExample) |
| AU (1) | AU2016226097B2 (enExample) |
| BR (1) | BR112017018767A2 (enExample) |
| ES (1) | ES3014555T3 (enExample) |
| IL (1) | IL254238B (enExample) |
| MX (2) | MX2017011251A (enExample) |
| RU (1) | RU2733286C2 (enExample) |
| SG (2) | SG11201707105TA (enExample) |
| TW (1) | TWI726870B (enExample) |
| WO (1) | WO2016141244A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| CN112500491B (zh) * | 2020-12-18 | 2022-04-08 | 深圳市迈加瑞生物技术有限公司 | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 |
| CN116179493A (zh) * | 2021-09-29 | 2023-05-30 | 成都美杰赛尔生物科技有限公司 | 敲除两种免疫检测点基因的免疫细胞及其制备方法与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| ES2146552B1 (es) * | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN101084007A (zh) | 2004-09-22 | 2007-12-05 | 金齐姆公司 | TGF－β拮抗剂限制免疫抑制剂肾毒性的用途 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| PL1874818T3 (pl) * | 2005-04-22 | 2011-09-30 | Lilly Co Eli | Przeciwciała swoiste wobec TGF-beta 1 |
| CA2632799A1 (en) | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| EP2006380A4 (en) | 2006-03-23 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR |
| CN101553254A (zh) | 2006-10-03 | 2009-10-07 | 建新公司 | TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途 |
| MX2011000071A (es) | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Inmunoterapeuticos de interleucina-6 (il6). |
| US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| US9409950B2 (en) * | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| JP6495884B2 (ja) * | 2013-03-11 | 2019-04-03 | ジェンザイム・コーポレーション | 改変抗ｔｇｆベータ抗体および抗原結合フラグメント |
| AU2014235933B2 (en) | 2013-03-20 | 2019-01-24 | Baylor College Of Medicine | Methods for treating osteogenesis imperfecta |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
-
2016
- 2016-03-02 TW TW105106243A patent/TWI726870B/zh active
- 2016-03-03 EP EP16710059.3A patent/EP3265484B1/en active Active
- 2016-03-03 RU RU2017134042A patent/RU2733286C2/ru active
- 2016-03-03 AR ARP160100559A patent/AR103839A1/es unknown
- 2016-03-03 BR BR112017018767A patent/BR112017018767A2/pt not_active IP Right Cessation
- 2016-03-03 SG SG11201707105TA patent/SG11201707105TA/en unknown
- 2016-03-03 MX MX2017011251A patent/MX2017011251A/es unknown
- 2016-03-03 KR KR1020237037758A patent/KR102754133B1/ko active Active
- 2016-03-03 AU AU2016226097A patent/AU2016226097B2/en not_active Ceased
- 2016-03-03 ES ES16710059T patent/ES3014555T3/es active Active
- 2016-03-03 KR KR1020257000711A patent/KR20250009587A/ko active Pending
- 2016-03-03 EP EP24220330.5A patent/EP4527850A3/en not_active Withdrawn
- 2016-03-03 SG SG10201912449UA patent/SG10201912449UA/en unknown
- 2016-03-03 WO PCT/US2016/020779 patent/WO2016141244A1/en not_active Ceased
- 2016-03-03 KR KR1020177027371A patent/KR102598790B1/ko active Active
- 2016-03-03 US US15/555,499 patent/US10508146B2/en active Active
- 2016-03-03 JP JP2017546178A patent/JP6845802B2/ja active Active
- 2016-03-03 CN CN201680025665.5A patent/CN107889491B/zh active Active
-
2017
- 2017-08-31 IL IL254238A patent/IL254238B/en unknown
- 2017-08-31 MX MX2022007456A patent/MX2022007456A/es unknown
-
2019
- 2019-10-30 US US16/669,211 patent/US11325971B2/en active Active
-
2022
- 2022-04-04 US US17/713,087 patent/US11976112B2/en active Active
-
2024
- 2024-04-04 US US18/627,131 patent/US12473356B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007456A (es) | Dimeros scfv-fc que se unen al factor de crecimiento transformante-?1 con alta afinidad, avidez y especificidad. | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| MX2018016364A (es) | Anticuerpos anti-pd-l1. | |
| CL2018001238A1 (es) | Moléculas de unión específicas para asct2 y usos de las mismas | |
| PE20161389A1 (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| EA201792055A1 (ru) | Антитела против cd48 и их конъюгаты | |
| CL2017001090A1 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
| UY36194A (es) | Anticuerpos anti-tau humanizados | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| CR20180065A (es) | Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| MX385456B (es) | Anticuerpos cd123 y conjugados de los mismos. | |
| CL2019001352A1 (es) | Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo. | |
| CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
| MX2019011585A (es) | Anticuerpos miltiespecificos estables. | |
| CL2019002894A1 (es) | Anticuerpo monoclonal para pd-l1. | |
| MX382703B (es) | ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD. | |
| WO2019147863A3 (en) | Mica/b antibodies and methods of use | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| BR112017022073A2 (pt) | método para purificação de proteína | |
| MX2019007984A (es) | Apareamiento preferido de dominios de anticuerpos. | |
| MX2016008794A (es) | Secuencias de anticuerpos especificos para e. coli. |